gms | German Medical Science

23rd Annual Meeting of the German Retina Society

German Retina Society

24.09. - 25.09.2010, Freiburg

Ruthenium plaque brachytherapy in vasoproliferative tumors of the retina

Meeting Abstract

  • Gregor Willerding - Charité, University School of Medicine Berlin, University Eye Clinic, Campus Virchow Clinic and Campus Benjamin Franklin, Berlin
  • K. Urban - Charité, University School of Medicine Berlin, University Eye Clinic, Campus Virchow Clinic and Campus Benjamin Franklin, Berlin
  • V. Kakkassery - Charité, University School of Medicine Berlin, University Eye Clinic, Campus Virchow Clinic and Campus Benjamin Franklin, Berlin
  • A. M. Joussen - Charité, University School of Medicine Berlin, University Eye Clinic, Campus Virchow Clinic and Campus Benjamin Franklin, Berlin

German Retina Society. 23rd Annual Conference of the German Retina Society. Freiburg i. Br., 24.-25.09.2010. Düsseldorf: German Medical Science GMS Publishing House; 2010. Doc10rg33

DOI: 10.3205/10rg33, URN: urn:nbn:de:0183-10rg333

This is the translated version of the article.
The original version can be found at: http://www.egms.de/de/meetings/rg2010/10rg33.shtml

Published: September 21, 2010

© 2010 Willerding et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

Introduction: Vasoproliferative tumors of the retina are lesions of unknown origin, developing with or without association to other intraocular findings. These benign lesions may reduce vision by complications like maculopathy, retinal detachment and central subretinal lipid deposition.

Methods: Retrospective interventional case series.

Results: 16 eyes in 16 pts were treated between 2001 and 2008 using Ruthenium Brachytherapy. VA was median 0.4 before and median 0,5 after therapy.Tumor height was 2.9 mm (mean) before and 1.6 mm (mean) after treatment. 5 patients received additional vitrektomy.

Conclusion: Brachytherapy may be useful in inducing regression of Vasoproliferative tumors of the retina but additional treatment seems to be reasonable in a significant number of patients.